TBR-760 in Adult Patients With Non-Functioning Pituitary Adenomas

Summary

This is a randomized, double-blind, placebo-controlled study to assess the safety, tolerability, efficacy, PK, and PD of the chimeric dopamine-somatostatin receptor agonist, TBR-760, in adult patients with NFPA over 52 weeks.

Timeline

Start

2020-05

Primary completion

2023-03

Completion

2023-06

Drugs

Indications